Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Čájet eará veršuvnnaid (1)

OBJECTIVE: To determine the relation between concentrations of prostate specific antigen at age 60 and subsequent diagnosis of clinically relevant prostate cancer in an unscreened population to evaluate whether screening for prostate cancer and chemoprevention could be stratified by risk. DESIGN: Ca...

Bibliográfalaš dieđut
Váldodahkkit:	Vickers, A, Cronin, A, Björk, T, Manjer, J, Nilsson, P, Dahlin, A, Bjartell, A, Scardino, P, Ulmert, D, Lilja, H
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2010

Geahča maid

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study
Dahkki: Vickers, A, et al.
Almmustuhtton: (2010)

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
Dahkki: Lilja, H, et al.
Almmustuhtton: (2011)

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
Dahkki: Klein, R, et al.
Almmustuhtton: (2012)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
Dahkki: Lilja, H, et al.
Almmustuhtton: (2008)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.
Dahkki: Ulmert, D, et al.
Almmustuhtton: (2008)

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2011)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
Dahkki: Savage, C, et al.
Almmustuhtton: (2010)

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))
Dahkki: Lilja, H, et al.
Almmustuhtton: (2008)

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
Dahkki: Ulmert, D, et al.
Almmustuhtton: (2008)

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
Dahkki: Evans-Axelsson, S, et al.
Almmustuhtton: (2012)

Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.
Dahkki: O'Brien, M, et al.
Almmustuhtton: (2011)

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
Dahkki: Lilja, H, et al.
Almmustuhtton: (2007)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2010)

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2007)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2010)

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
Dahkki: Christensson, A, et al.
Almmustuhtton: (2011)

Five genetic variants associated with prostate cancer.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2008)

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2009)

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
Dahkki: Ulmert, D, et al.
Almmustuhtton: (2009)

Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
Dahkki: Siivola, P, et al.
Almmustuhtton: (2000)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
Dahkki: Cao, Y, et al.
Almmustuhtton: (2002)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
Dahkki: Steuber, T, et al.
Almmustuhtton: (2007)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2011)

Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.
Dahkki: Ulmert, D, et al.
Almmustuhtton: (2006)

Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
Dahkki: Wenske, S, et al.
Almmustuhtton: (2009)

Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
Dahkki: Ulmert, D, et al.
Almmustuhtton: (2012)

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2009)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
Dahkki: Michael Tzeng, et al.
Almmustuhtton: (2021-08-01)

Biology of prostate-specific antigen
Dahkki: Lilja, H
Almmustuhtton: (2003)

Biology of prostate-specific antigen.
Dahkki: Lilja, H
Almmustuhtton: (2003)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2010)

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
Dahkki: O'Brien, M, et al.
Almmustuhtton: (2009)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2010)

The continuing role of prostate-specific antigen as a marker for localized prostate cancer: 'do not throw the baby out with the bath water'.
Dahkki: Challacombe, B, et al.
Almmustuhtton: (2009)

Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
Dahkki: Olsson, A, et al.
Almmustuhtton: (2005)

Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
Dahkki: Klein, R, et al.
Almmustuhtton: (2010)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2008)

Screening for prostate cancer: an update.
Dahkki: Shariat, S, et al.
Almmustuhtton: (2008)

Tumor markers in prostate cancer I: blood-based markers.
Dahkki: Shariat, S, et al.
Almmustuhtton: (2011)

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
Dahkki: Haese, A, et al.
Almmustuhtton: (2004)